

Title (en)

GENE THERAPY WITH MODIFIED p65 PROTEINS

Title (de)

GENTHERAPIE MIT MODIFIZIERTEN P65 PROTEINEN

Title (fr)

THERAPIE GENIQUE A L'AIDE DE PROTEINES p65 MODIFIEES

Publication

EP 0854921 A1 19980729 (EN)

Application

EP 96933407 A 19960926

Priority

- EP 9604216 W 19960926
- US 433995 P 19950926

Abstract (en)

[origin: WO9712040A1] A method to render mammalian, particularly endothelial cells less susceptible to platelet- and leukocyte-mediated injury and inflammation is described, comprising genetically modifying the cells by inserting DNA encoding a transdominant inhibitor of a Re1A (p65) protein, and expression functional inhibitor in the modified cells under cellular activating conditions, whereby Re1A (i.e. NF kappa B) transactivation of genes is suppressed, and corresponding proteins and DNA therefor. The method, which can be carried out in vivo, ex vivo or in vitro, has use in allogeneic or xenogeneic transplantation as well as to treat systemic or local inflammatory conditions.

IPC 1-7

C12N 15/12; **A01K 67/027**; **C12N 5/10**; **A61K 48/00**; **C07K 14/47**

IPC 8 full level

A01K 67/027 (2006.01); **C07K 14/47** (2006.01); **C12N 15/12** (2006.01); **C12N 15/85** (2006.01); **A61K 38/00** (2006.01); **A61K 48/00** (2006.01)

CPC (source: EP)

A01K 67/0275 (2013.01); **C07K 14/4702** (2013.01); **C12N 15/8509** (2013.01); **A01K 2217/05** (2013.01); **A01K 2217/20** (2013.01); **A01K 2227/105** (2013.01); **A01K 2267/025** (2013.01); **A01K 2267/03** (2013.01); **A01K 2267/0368** (2013.01); **A61K 38/00** (2013.01); **A61K 48/00** (2013.01)

Citation (search report)

See references of WO 9712040A1

Cited by

US11786556B2

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9712040 A1 19970403; AU 7215596 A 19970417; CA 2233031 A1 19970403; EP 0854921 A1 19980729

DOCDB simple family (application)

EP 9604216 W 19960926; AU 7215596 A 19960926; CA 2233031 A 19960926; EP 96933407 A 19960926